Category Archives: Genetic Engineering

John Sterling | 05/01/2014

The following article, reproduced in full below, was originally published at Genetic Engineering & Biotechnology News.

Its been a hot year for biotech! As G. Steven Burrill, CEO of Burrill & Co., noted in a recent report, life science firms raised $2.9 billion in new equity capital globally from public investors in February. This included $1.1 billion raised by 18 companies that completed initial public offerings and $1.8 billion raised by 23 companies that completed follow-on offerings during the month.

In the U.S., 16 life sciences companies raised $959 million through IPOs and 22 companies raised $1.75 billion through follow-on offerings on U.S. exchanges during February, making the month the biggest for IPOs in terms of the number of completed deals since February 2000!

Why the excitement? Promising new biotherapeutics are emerging from the drug pipeline. Advances in stem cell research and regenerative medicine are occurring at a rapid pace. And OMICS technologies (e.g., genomics, proteomics, metabolomics, transcriptomics, glycomics, and lipomics), originally developed and used in the lab, are now making their way into clinical medicine, truly ready to usher in an era of personalized medicine.

The 2014 BIO International Convention will be held in San Diego this June. As usual, the BIO conference committee did a superb job in putting together a first-class program that covers a wide range of topics with something to offer everyone involved in biotech R&D or commercialization. Its been a tough call this year but here are my picks for the top 10 cant miss sessions at the conference.

To learn more about the program and available registration packages for Convention, please visithere

John Sterling is editor-in-chief of Genetic Engineering & Biotechnology News (GEN).

See the original post here:
GENs Top 10 Session Picks for the 2014 BIO International Convention

Today virtually everything we eat is produced from seeds that have been genetically altered in some way. New methods of plant tinkering have emerged over the generations and so, too, have the fears

Today virtually everything we eat is produced from seeds that have been genetically altered in one way or another. Credit: Thinkstock

Editor's note: The following is the introduction to the May 2014 issue of Scientific American Classics: The Birth of the Great GMO Debate.

The idea of intentionally infecting a plant with a bacterium might seem strange. Just three decades ago, however, researchers discovered that they could use this infection to deliver new and potentially useful genes into crops.

What has long appeared to be simply the agent of a bothersome plant disease is likely to become a major tool for the genetic manipulation of plants: for putting new genes into plants and thereby giving rise to new varieties with desired traits, announced acclaimed scientist Mary-Dell Chilton in 1983 in a pioneering article, one of many in this collection from the archives of Scientific American. Today genes introduced this way are yielding some of the most exciting new approaches to food securityas well as a hearty amount of debate.

Despite the excitement about the potential benefits of genetic engineering 30 years ago, the broader historical perspective highlighted in this collection reveals that this is just one of many thrilling and surprising advances in the long history of plant genetic alteration, which began well before this retrospective issue could document. (Scientific American extends back only to 1845.) Consider the assessment of the new technology of cross-pollination described in 1717 by botanist Richard Bradley: A curious person may by this knowledge produce such rare kinds of plants as have not yet been heard of.

For 10,000 years, in fact, we have altered the genetic makeup of our crops. For example, the ancient ancestor of modern corn was created some 6,000 years ago by Native Americans who domesticated a wild plant called teosinte, which looks nothing like a modern corn plant. If humans still depended on this wild relative, we would need hundreds, if not thousands, of times more plantsand acresto replace corn.

Today virtually everything we eat is produced from seeds that have been genetically altered in one way or another. The old approaches were crude and have been refined over the centuries. Modern methods include grafting and forced pollination (mixing genes of distantly related species) and radiation treatments to create random mutations in seeds. The newest method is genetic engineeringa technology developed after scientists observed that the bothersome plant pathogen Agrobacterium tumefaciens habitually introduced its own genes into plants. With a little laboratory work, the bacterium can instead implant desirable genes, such as those that increase nutrients or help the plant resist pests or drought.

The planting of genetically engineered crops during the past 20 years has drastically reduced the amount of synthetic insecticides sprayed worldwide, shifted the use of herbicides to those that are less toxic, rescued the U.S. papaya industry from disease, and benefited the health and well-being of farmers and their families and consumers. Every scientific review of the crops on the market so far has concluded that the plants are safe to eat.

Just as the excitement surrounding the benefits of genetic engineering paralleled those of our predecessors, so, too, has the fear of plant tinkering technologies persisted over time. Consider the comments of Maxwell T. Masters, president of the International Conference of Hybridization, in his 1899 Scientific American article: Many worthy people objected to the production of hybrids on the ground that it was an impious interference with the laws of Nature. Today we are all too familiar with similar arguments about the application of genetic engineering in agriculture.

See more here:
Plant Engineers Sow Debate

Genetic Engineering and Insulin
CSE 684 Assignment #3.

By: Amanda Tuss

Go here to read the rest:
Genetic Engineering and Insulin - Video

Human Genetic Engineering Final Project

By: Jazmine Byrd

Read more here:
Human Genetic Engineering Final Project - Video

Genetic engineering and transgenic organisms

By: JCauthers

See the rest here:
Genetic engineering and transgenic organisms - Video

An overview of Genetic Engineering 2
Genetic Engineering 2 -- better workflows, more productive post.

By: QuantelOnline

See the original post:
An overview of Genetic Engineering 2 - Video

TTA14-OGM-Genetic Engineering
TTA14-OGM-Genetic Engineering.

By: Sallie Hill Outten

Original post:
TTA14-OGM-Genetic Engineering - Video

PUBLIC RELEASE DATE:

30-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 30, 2014James M. Wilson, MD, PhD (University of Pennsylvania Perelman School of Medicine, Philadelphia) has dedicated his research and medical career to developing gene therapy and the vectors needed to deliver genes into cells for the treatment and cure of inherited diseases. In recognition of his leadership and accomplishments, Dr. Wilson has received a Pioneer Award, bestowed by a blue ribbon panel*, from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by honoring the leading 12 Pioneers in the field of cell and gene therapy and publishing a Pioneer Perspective by each of the award recipients. The Perspective by Dr. Wilson is available on the Human Gene Therapy website.

In his essay "Genetic Diseases, Immunology, Viruses, and Gene Therapy," Dr. Wilson traces the path, motivating factors, and mentors and colleagues that led him from his early work identifying the mutations responsible for the devastating childhood disease Lesch-Nyhan syndrome (LNS) to the exploration of novel techniques and molecular tools for transferring therapeutic genes first into animals and then into humans. Since joining the faculty at the University of Pennsylvania more than 20 years ago, much of his research has focused on the development of adenoviral and adeno-associated viral vectors as vehicles for gene delivery.

Noting that the commercialization of gene therapy is still in its infancy, Dr. Wilson states that "We are entering a remarkable era of gene therapy research that will accelerate its development and lead to a number of commercial products across a spectrum of diseases." His laboratory has made seminal contributions to the basic biology of vectors and the development of current generation vector technologies that have enabled others to successfully move into the clinic.

"Dr. Wilson strongly deserves this accolade as an HGT pioneer of gene and cell therapy," says Deputy Editor George Dickson, BSc, PhD, University of London, Surrey. "His unparalleled contributions to the adenoviral and AAV vector fields over more than 25 years have been profound and seminal. Vectors from Dr. Wilson's lab at the University of Pennsylvania have been distributed around the globe, and are bearing fruit in viral vaccine and viral gene therapy areas spanning a plethora of disease targets."

###

*The blue ribbon panel of leaders in cell and gene therapy, led by Chair Mary Collins, PhD, MRC Centre for Medical Molecular Virology, University College London selected the Pioneer Award recipients. The Award Selection Committee selected scientists that had devoted much of their careers to cell and gene therapy research and had made a seminal contribution to the field--defined as a basic science or clinical advance that greatly influenced progress in translational research.

About the Journal

Here is the original post:
James Wilson, M.D., Ph.D. receives Pioneer Award

The Henoch Prophecies from the Billy Meier Contacts. [EN]
If you like prophecies, there is nobody with a track record like the Plejarans. They tell Billy Meier and he makes them available to us. They have an amazing. The Henoch Prophecies from the...

By: Seluk Polat

Here is the original post:
The Henoch Prophecies from the Billy Meier Contacts. [EN] - Video

ST. PAUL A produced with genetic engineering label could one day make its appearance in Minnesota stores.

Rep. Karen Clark, D-Minneapolis, sponsors a bill to regulate disclosure of genetically engineered food and seed. The House commerce committee held an informational hearing on the bill Thursday. There is no Senate companion and the House committee took no vote.

This is a bill about the basic right of consumers to know whats in their food whether or not their food contains genetically modified compounds, Clark said.

According to the bill, genetically modified foods for sale would be required to have a label conspicuously placed on the packaging or shelf (for unpackaged foods) that says produced with genetic engineering.

Genetically modified seed would have such labeling on the seed container, receipt or other form of product identification.

The bill also consists of enforcement provisions and a section describing some research into the negative effects of genetically engineered food such as herbicide resistance in weeds and an increase in the use of insecticides.

Perry Aasness, executive director of the Minnesota Agri-Growth Council, said that science has shown that genetically engineered foods are essentially identical to conventional varieties and pose no greater risk than non-GMO food products.

He said that he is not opposed to labeling requirements, but believes the federal government, through the Food and Drug Administration, should develop voluntary labeling standards.

Jamie Pfuhl, president of the Minnesota Grocers Association, agreed with allowing the federal government to enact labeling legislation. A state-by-state approach would create a patchwork of regulations, she said, a challenge for stores that receive products from other states and countries.

Foods exempted from the labeling requirements under the bill would include:

Read more:
Minn. lawmakers consider GMO label